Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a premier U.S. biotechnology corporation with a market capitalization of $96.60 billion as of November 5, 2026, FY2025 revenues of $14.34 billion, GAAP net income of $4.50 billion, and 15,410 full-time employees. Led since its 1988 founding by physician-scientists Leonard S. Schleifer and George D. Yancopoulos, Regeneron ranks among the top global biopharmaceutical innovators in immunology, ophthalmology, and oncology.

Industry Position

Regeneron occupies a leading position in the global monoclonal antibody and biologics sector, anchored by four marketed blockbuster medicines: Dupixent, EYLEA, EYLEA HD, and Libtayo. Dupixent (dupilumab), co-developed with Sanofi, is the world's most widely prescribed innovative branded antibody medicine, treating over 1.4 million active patients globally across atopic dermatitis, asthma, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, and chronic spontaneous urticaria (CSU). In Q3 2026, global Dupixent net sales recorded by Sanofi surged 35% year-over-year to $6.50 billion (an annualized run rate of $26.0 billion), driving Regeneron's Sanofi collaboration revenue up 30% in FY2025 to $5.88 billion and up 68% in Q3 2026 to $2.70 billion. In ophthalmology, Regeneron commands a dominant U.S. anti-VEGF retinal franchise that generated $4.39 billion in FY2025 U.S. net sales and $1.42 billion in ex-U.S. Bayer collaboration revenue. In immuno-oncology, wholly owned Libtayo (cemiplimab) is the standard-of-care PD-1 inhibitor in non-melanoma skin cancers, achieving $1.50 billion in FY2025 global net sales and expanding 51% year-over-year in Q3 2026 to $550 million following FDA, European Commission, and Japanese approvals in adjuvant cutaneous squamous cell carcinoma (CSCC).

Competitive Advantages

Regeneron's core competitive moat stems from its internally built, end-to-end discovery and human genetics engine rather than external mega-mergers. Its VelociSuite platform – centered on VelocImmune mice genetically humanized to produce fully human monoclonal and bispecific antibodies – has generated all 15 of Regeneron's FDA-approved or authorized medicines and approximately 50 active clinical candidates. This biological engineering capability is paired with the Regeneron Genetics Center (RGC), which has sequenced more than 2.7 million human exomes linked to de-identified electronic health records to identify and validate novel genetic drug targets such as ANGPTL3, GPR75, and C5. Financially, Regeneron's profit-sharing structure with Sanofi reached a major inflection point at the end of Q2 2026 when the historical Sanofi development balance was fully repaid, allowing Regeneron to capture its full contractual share of global Dupixent profits starting in Q3 2026. The company also maintains a fortress balance sheet with $40.56 billion in total assets and $31.26 billion in stockholders' equity at year-end 2025 (rising to $44.41 billion in assets and $33.50 billion in equity by September 30, 2026), supporting $5.15 billion in FY2025 GAAP R&D investment (35.9% of revenue) alongside $3.80 billion in FY2025 shareholder buybacks and dividends.

Strategic Expansion

To extend its growth trajectory into the 2030s, Regeneron is executing a multi-pronged pipeline and manufacturing expansion. In retinal diseases, the company is actively transitioning patients from standard EYLEA (2 mg) to EYLEA HD (8 mg), which gained FDA approval in November 2025 for retinal vein occlusion (RVO) and monthly dosing flexibility; U.S. EYLEA HD sales rose 36% to $1.64 billion in FY2025 and jumped 62% year-over-year to $699 million in Q3 2026. In October 2026, Regeneron expanded its strategic alliance with Sanofi to develop four next-generation, long-acting immunology antibodies, securing a $1.0 billion upfront payment to be recognized in Q4 2026 and up to $7.0 billion in potential milestones. Recent regulatory wins include the 2025 FDA approval of Lynozyfic (linvoseltamab, BCMAxCD3 bispecific antibody) for relapsed/refractory multiple myeloma and the 2026 FDA approval of Pasatru (garetosmab) for fibrodysplasia ossificans progressiva (FOP), alongside late-stage programs in melanoma (fianlimab LAG-3 plus Libtayo), complement-mediated diseases (cemdisiran and pozelimab), genetic hearing loss (DB-OTO gene therapy), and metabolic/obesity combinations (olatorepatide and trevogrumab). Operationally, Regeneron has committed over $9.0 billion to U.S. infrastructure, highlighted by a $2.0 billion bulk manufacturing plant in Saratoga Springs, New York.

Risks & Outlook

Key risks center on competitive erosion in the U.S. retinal franchise and therapeutic concentration. Standard EYLEA U.S. net sales declined 42% in FY2025 to $2.75 billion due to competition from Roche's Vabysmo and emerging aflibercept biosimilars, requiring continued execution on EYLEA HD adoption and pre-filled syringe supply expansion. Additionally, with GAAP R&D projected to rise to $6.45 billion – $6.68 billion in FY2026, clinical trial setbacks in pivotal Phase 3 oncology, hematology, or obesity programs or U.S. Medicare drug price negotiation pressures under the Inflation Reduction Act could weigh on margins. Nevertheless, the full repayment of the Sanofi development balance, surging Dupixent and EYLEA HD cash flows, and Q3 2026 revenue growth of 36% to $5.10 billion underscore exceptional fundamental momentum, earning Regeneron Pharmaceuticals a VerityRank Score of 88/100.